WallStreetZenWallStreetZen

NYSE: ELAN
Elanco Animal Health Inc Stock

$9.08-0.39 (-4.12%)
Updated Mar 22, 2023
ELAN Price
$9.08
Fair Value Price
N/A
Market Cap
$4.46B
52 Week Low
$9.03
52 Week High
$27.68
P/E
-56.75x
P/B
0.61x
P/S
1.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.41B
Earnings
-$78.00M
Gross Margin
56.6%
Operating Margin
3.83%
Profit Margin
-1.8%
Debt to Equity
1.13
Operating Cash Flow
$452M
Beta
0.98
Next Earnings
May 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ELAN Overview

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for companion and food animals. It offers companion animal disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production. The company sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. The company has a research and development collaboration with AgBiome, Inc. to develop nutritional health products for swine; and strategic alliance with the Purdue University and Purdue Research Foundation. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELAN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ELAN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ELAN is good value based on its book value relative to its share price (0.61x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.79x)
P/B vs Industry Valuation
ELAN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ELAN due diligence checks available for Premium users.

Be the first to know about important ELAN news, forecast changes, insider trades & much more!

ELAN News

Valuation

ELAN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-56.75x
Industry
17.73x
Market
22.44x

ELAN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.61x
Industry
1.79x
ELAN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ELAN's financial health

Profit margin

Revenue
$981.0M
Net Income
-$55.0M
Profit Margin
-5.6%
ELAN's Earnings (EBIT) of $169.00M... subscribe to Premium to read more.
Interest Coverage Financials
ELAN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$15.5B
Liabilities
$8.2B
Debt to equity
1.13
ELAN's short-term assets ($3.28B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELAN's long-term liabilities ($6.50B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELAN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ELAN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$13.0M
Investing
-$76.0M
Financing
-$84.0M
ELAN's operating cash flow ($452.00M)... subscribe to Premium to read more.
Debt Coverage Financials

ELAN vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ELAN$4.46B-4.12%-56.75x0.61x
PRGO$4.58B-1.71%-32.67x0.94x
EVO$3.43B+1.15%-1.14x2.76x
ALVO$3.37B+0.30%-5.21x-5.97x
BHC$2.74B-4.29%-12.23x-3.97x

Elanco Animal Health Stock FAQ

What is Elanco Animal Health's quote symbol?

NYSE: ELAN) Elanco Animal Health trades on the NYSE under the ticker symbol ELAN. Elanco Animal Health stock quotes can also be displayed as NYSE: ELAN.

If you're new to stock investing, here's how to buy Elanco Animal Health stock.

What is the 52 week high and low for Elanco Animal Health (NYSE: ELAN)?

(NYSE: ELAN) Elanco Animal Health's 52-week high was $27.68, and its 52-week low was $9.03. It is currently -67.2% from its 52-week high and 0.61% from its 52-week low.

How much is Elanco Animal Health stock worth today?

(NYSE: ELAN) Elanco Animal Health currently has 491,543,501 outstanding shares. With Elanco Animal Health stock trading at $9.08 per share, the total value of Elanco Animal Health stock (market capitalization) is $4.46B.

Elanco Animal Health stock was originally listed at a price of $36.00 in Sep 20, 2018. If you had invested in Elanco Animal Health stock at $36.00, your return over the last 4 years would have been -74.78%, for an annualized return of -29.13% (not including any dividends or dividend reinvestments).

How much is Elanco Animal Health's stock price per share?

(NYSE: ELAN) Elanco Animal Health stock price per share is $9.08 today (as of Mar 22, 2023).

What is Elanco Animal Health's Market Cap?

(NYSE: ELAN) Elanco Animal Health's market cap is $4.46B, as of Mar 24, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Elanco Animal Health's market cap is calculated by multiplying ELAN's current stock price of $9.08 by ELAN's total outstanding shares of 491,543,501.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.